Literature DB >> 10677415

Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

L Faber1, A Meissner, P Ziemssen, H Seggewiss.   

Abstract

OBJECTIVE: To determine the long term outcome in patients treated with percutaneous transluminal septal myocardial ablation (PTSMA) for hypertrophic obstructive cardiomyopathy (HOCM). DESIGN AND
SETTING: Observational, single centre study. PATIENTS: 25 patients (13 women, 12 men, mean (SD) age 54.7 (15.0) years) with drug treatment resistant New York Heart Association (NYHA) class 2.8 (0. 6) symptoms attributed to a high left ventricular outflow gradient (LVOTG) and a coronary artery anatomy suitable for intervention. INTERVENTION: PTSMA by injection of 4.1 (2.6) ml of alcohol (96%) into 1.4 (0.6) septal perforator arteries to ablate the hypertrophied interventricular septum. OUTCOME MEASURES: During in-hospital follow up, enzyme rise, the frequency of atrioventricular conduction lesions requiring permanent DDD pacing, and in-hospital mortality were assessed. Long term follow up (30 (4) months, range 24-36 months) included symptoms, echocardiographic measurements of left atrial and left ventricular dimensions and function, and LVOTG.
RESULTS: Mean postinterventional creatine kinase rise was 780 (436) U/l. During PTSMA 13 patents developed total heart block, permanent pacing being necessary in five of them. One 86 year old patient died from ventricular fibrillation associated with intensive treatment (beta mimetic and theophylline) for coexistent severe obstructive airway disease. After three months, three patients underwent re-PTSMA because of a dissatisfactory primary result, leading to LVOTG elimination in all of them. During long term follow up, LVOTG showed sustained reduction (3 (6) mm Hg at rest and 12 (19) mm Hg with provocation) associated with stable symptomatic improvement (NYHA class 1.2 (1.0)) and without significant global left ventricular dilatation.
CONCLUSIONS: PTSMA is an effective non-surgical technique for reduction of symptoms and LVOTG in HOCM. Prospective, long term observations of larger populations are necessary in order to determine the definitive significance of the procedure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677415      PMCID: PMC1729336          DOI: 10.1136/heart.83.3.326

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  20 in total

1.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients.

Authors:  C Knight; A S Kurbaan; H Seggewiss; M Henein; M Gunning; D Harrington; D Fassbender; U Gleichmann; U Sigwart
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

Review 2.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

Authors:  E D Wigle; H Rakowski; B P Kimball; W G Williams
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

3.  Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy.

Authors:  R B McCully; R A Nishimura; A J Tajik; H V Schaff; G K Danielson
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

4.  Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy.

Authors:  E Braunwald
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

Review 5.  The clinical course of heart failure and its modification by ACE inhibitors: insights from recent clinical trials.

Authors:  J G Cleland
Journal:  Eur Heart J       Date:  1994-01       Impact factor: 29.983

6.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

7.  [Catheter treatment of hypertrophic obstructive cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  Dtsch Med Wochenschr       Date:  1996-05-24       Impact factor: 0.628

8.  Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study.

Authors:  R A Nishimura; D L Hayes; D M Ilstrup; D R Holmes; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1996-02       Impact factor: 24.094

9.  Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value.

Authors:  K Hina; S Kusachi; K Iwasaki; K Nogami; H Moritani; T Kita; G Taniguchi; T Tsuji
Journal:  Clin Cardiol       Date:  1993-05       Impact factor: 2.882

Review 10.  The management of hypertrophic cardiomyopathy.

Authors:  P Spirito; C E Seidman; W J McKenna; B J Maron
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245

View more
  18 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

2.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

3.  A case of ventricular asystole without escape rhythm 4 days after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy with drug-resistant paroxysmal atrial fibrillation.

Authors:  Mitsunori Ohtsubo; Hiroto Sakai; Hisashi Kon; Hideyuki Takano
Journal:  J Cardiol Cases       Date:  2011-08-11

4.  Symptomatic hypertrophic obstructive cardiomyopathy: semi-supine bicycle ergometry as a useful provocative manoeuvre to elicit latent gradient.

Authors:  Sanjay Kumar Dhar; Vatchsala Varadharajan; Abdallah Al-Mohammad; Julie Sandoval; Ever D Grech
Journal:  BMJ Case Rep       Date:  2009-03-31

5.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

6.  Hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  Konstantinos I Stroumpoulis; Ioannis N Pantazopoulos; Theodoros T Xanthos
Journal:  World J Cardiol       Date:  2010-09-26

Review 7.  Mechanisms and efficacy of LV pre-excitation for patients with heart failure and supra-normal systolic function.

Authors:  D A Kass
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

Review 8.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

10.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.